Blood test may predict MS activity in newly diagnosed patients

Credibility

Interest

Key Takeaway

A blood test measuring neurofilament light (sNfL) can help predict whether newly diagnosed, untreated MS patients will stay free of disease activity over time.

What They Found

Researchers measured a protein in the blood called serum neurofilament light (sNfL), which rises when nerve fibers are injured. Higher sNfL levels were linked to MRI signs of active inflammation called gadolinium-enhancing lesions, but not clearly linked to older scar-like lesions seen on T2 MRI scans. Patients who had not yet started MS treatment and who had high sNfL were less likely to reach “No Evidence of Disease Activity-3” (NEDA-3), meaning they were more likely to have relapses, MRI changes, or disability progression. People already on MS medicines tended to have lower sNfL levels at the first test, suggesting treatment can lower this marker. Overall, a single high sNfL result in treatment-naive patients signaled a higher chance of future disease activity during follow-up.

Who Should Care and Why

People newly diagnosed with MS and their caregivers should care because a simple blood test may give early clues about how active the disease is and how likely it is to stay quiet. Think of sNfL like a smoke alarm: a louder alarm (higher sNfL) suggests active fire (nerve damage) and might prompt quicker action. Doctors and MS nurses can use this information to decide whether to start treatment sooner or choose a stronger therapy, similar to choosing a stronger umbrella when heavy rain is expected. Caregivers can use the result to plan for closer monitoring and to help patients make informed choices about treatment. Patients already on treatment may find lower sNfL reassuring, but any high value should lead to discussion with the care team.

Important Considerations

This study followed a modest number of patients and only measured sNfL once at the start, so it can’t prove cause and effect or predict every individual outcome. The findings were strongest in patients who hadn’t started treatment yet, so results may not apply the same way to people already on MS medicines. Also, sNfL can be influenced by age, body size, or other conditions that damage nerves, so doctors interpret the number alongside other tests and symptoms.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics Treatment Updates Early Research

Article Topics:

BiomarkerMultiple sclerosisNEDA-3Predictive valueSerum neurofilament light chain

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News